Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.
As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.
Read the HAH Bulletin to find out more.